Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondo T, Abe O, Kikuchi K, Tanabe T, Ogawa N
Gan To Kagaku Ryoho. 1985 Sep;12(9):1850-63.
An analysis of 3,630 gastric cancer cases from 412 institutions who were treated with 6 randomly-assigned protocols was carried out to study the effect of daily PSK and Futraful administration and the adjuvant effect of PSK and/or Picibanil (OK 5 KE) combined with MMC and FT. Evaluation of immunochemotherapy was made on the basis of three-year survival rates and immunoparameters. The most positive results were found in survival rates favoring the combined therapy (FT + PSK) over single administration (FT) to relatively early-stage patients (30%, difference), PSK, MMC and FT combination (10%), and PSK, OK, MMC and FT (22%), over single chemotherapy alone. Serum alpha-2 globulin levels, indicative of immunosuppression, were lower in PSK-administered cases. The overall findings indicated that PSK and/or OK with MMC and FT are effective in prolonging the lives of post-operative patients.
对来自412个机构的3630例胃癌病例进行了分析，这些病例采用6种随机分配的方案进行治疗，以研究每日服用PSK和氟尿嘧啶的效果以及PSK和/或匹鲁卡品（OK 5 KE）与丝裂霉素和氟尿嘧啶联合使用的辅助效果。基于三年生存率和免疫参数对免疫化疗进行了评估。在相对早期患者中，联合治疗（氟尿嘧啶+PSK）比单一用药（氟尿嘧啶）的生存率最具优势（30%，差异），PSK、丝裂霉素和氟尿嘧啶联合治疗（生存率为10%），以及PSK、OK、丝裂霉素和氟尿嘧啶联合治疗（生存率为22%）比单纯单一化疗更具优势。服用PSK的病例中，指示免疫抑制的血清α-2球蛋白水平较低。总体研究结果表明，PSK和/或OK与丝裂霉素和氟尿嘧啶联合使用可有效延长术后患者的生命。
